Bone Abstracts

Introduction: Patients with multiple myeloma (MM) commonly present with devastating bone disease mediated by increased bone resorption and suppressed bone formation. We have previously shown that blocking activity of the Wnt antagonist Dkk-1 promotes osteoblastogenesis and inhibits development of bone lesions in experimental models of MM. In the 5T murine models of MM, tumour cells home to the bone marrow. Injection of 5T2MM cells into C57BLKalwRij mice results in bone disease...

Destructive bone lesions due to osteolytic bone disease (OBD) are a major cause of morbidity and mortality in multiple myeloma (MM) patients and the development of new therapeutic strategies is of great interest. In this study, we assessed the effect of SRC inhibition with saracatinib (AZD0530, AstraZeneca) on the development of MM and its associated OBD. We first determined SRC family kinase expression in the MM microenvironment and found that myeloma cells express SRC at low...